Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Wendy Deenik"'
Autor:
Diana Al-Sarayfi, Mirian Brink, Martine E. D. Chamuleau, Rolf Brouwer, Roos van Rijn, Djamila Issa, Wendy Deenik, Gerwin Huls, Rogier Mous, Joost S.P. Vermaat, Josee M. Zijlstra, Tom van Meerten, Marcel Nijland
Publikováno v:
HemaSphere, Vol 7, p e48093ff (2023)
Externí odkaz:
https://doaj.org/article/bcc7bf57df004e8e88c1b8bf6eea0e9a
Autor:
Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multip
Externí odkaz:
https://doaj.org/article/ed3611ab0ceb40df9134edf248aba092
Autor:
Joost S. Vermaat, Sebastiaan F. Somers, Liesbeth C. de Wreede, Willem Kraan, Ruben A.L. de Groen, Anne M. R. Schrader, Emile D. Kerver, Cornelis G. Scheepstra, Henriëtte Berenschot, Wendy Deenik, Jurgen Wegman, Rianne Broers, Jan-Paul D. de Boer, Marcel Nijland, Tom van Wezel, Hendrik Veelken, Marcel Spaargaren, Arjen H. Cleven, Marie José Kersten, Steven T. Pals
Publikováno v:
Haematologica, Vol 105, Iss 2 (2020)
The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. A subset of DLBCL, howev
Externí odkaz:
https://doaj.org/article/93ed3bb67e6c40e09d22bd1f61cc4a61
Autor:
Wendy Deenik, Jeroen J.W.M. Janssen, Bronno van der Holt, Gregor E.G. Verhoef, Willem M. Smit, Marie José Kersten, Simon M.G.J. Daenen, Leo F. Verdonck, Augustin Ferrant, Anton V.M.B. Schattenberg, Pieter Sonneveld, Marinus van Marwijk Kooy, Shulamit Wittebol, Roelof Willemze, Pierre W. Wijermans, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk, Gert J. Ossenkoppele, Jan J. Cornelissen
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-5
Externí odkaz:
https://doaj.org/article/52ff014faa724e5c9930e7aea97fd445
Autor:
Marcel Spaargaren, Marie José Kersten, Liesbeth C. de Wreede, Wendy Deenik, Jan-Paul D. de Boer, Arjen H.G. Cleven, Henriette Berenschot, Marcel Nijland, Emile D. Kerver, Rianne Broers, Jurgen Wegman, Hendrik Veelken, Sebastiaan F Somers, Cornelis G. Scheepstra, Steven T. Pals, Joost S.P. Vermaat, Anne M. R. Schrader, Ruben A.L. de Groen, Tom van Wezel, Willem Kraan
Publikováno v:
Haematologica, 105(2), 424-434. FERRATA STORTI FOUNDATION
Haematologica, 105(2), 424-434. Ferrata Storti Foundation
Haematologica
Haematologica, 105(2), 424-434. Ferrata Storti Foundation
Haematologica
The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. A subset of DLBCL, howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e85f18c77e3a33989ef131aa620c26a4
https://research.rug.nl/en/publications/47497d5d-a291-4310-823e-822931123e0c
https://research.rug.nl/en/publications/47497d5d-a291-4310-823e-822931123e0c
Autor:
Annette W.G. van der Velden, Bronno van der Holt, Gerard M. J. Bos, Harm Sinnige, Anders Waage, Ulf-Henrik Mellqvist, Damian L. Szatkowski, Klaas G. van der Hem, Markus Hansson, Peter Gimsing, Pieter Sonneveld, Juleon Coenen, Morten Salomo, Rineke B. L. Leys, Einar Haukås, Lene Kongsgaard Nielsen, Sonja Zweegman, Mark-David Levin, Saskia K. Klein, Niels Abildgaard, Heleen Visser-Wisselaar, Wendy Deenik, Maja Hinge, Matthijs Westerman, Birgit I. Lissenberg-Witte, Claudia A.M. Stege, Niels W.C.J. van de Donk
Publikováno v:
SSRN Electronic Journal.
Background: The overall survival of patients with Multiple Myeloma has improved due to effective, often continuous, therapy. However, knowledge on the impact of long term treatment on health-related quality of life (HRQoL) is limited. Methods: The HO
Autor:
Wendy Deenik, Willem M. Smit, Jeroen Janssen, Noortje Thielen, Gert J. Ossenkoppele, Pieter Sonneveld, Gregor Verhoef, Peter J. M. Valk, J.H. Frederik Falkenburg, Harm Sinnige, Rianne A. H. M. Ammerlaan, Anton Schattenberg, Isabel W. T. Chu, M. Schipperus, Bronno van der Holt, Jan J. Cornelissen, Rien van Marwijk Kooy, Marie José Kersten
Publikováno v:
Annals of Hematology, 92, 8, pp. 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56
Item does not contain fulltext Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter, ran
Autor:
Bronno van der Holt, Anders Waage, Niels W.C.J. van de Donk, E. (Vera) J. M. Mattijssen, M. (Rineke) B. L. Leys, Annette W. G. van der Velden, Mark-David Levin, Harm Sinnige, Klaas G. van der Hem, Morten Salomo, Bea Tanis, Einar Haukås, Ulf-Henrik Mellqvist, Matthijs Westerman, Rolf Brouwer, Pieter Sonneveld, Saskia K. Klein, Astrid Gruber, Gerard M. J. Bos, Marian Stevens-Kroef, Markus Hansson, Damian L. Szatkowski, Wendy Deenik, Torben Plesner, Sonja Zweegman, Marc Durian, Heleen Visser-Wisselaar, Juleon Coenen
Publikováno v:
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M R B L, Sinnige, H A M, Haukås, E, van der Hem, K G, Durian, M F, Mattijssen, E V J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation. Long-term treatment with thalidomide is hampered by ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27be0ae01cb43dea87bdd45a3473c8b5
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9
Autor:
Gerrit Jan Schuurhuis, Jeroen Janssen, Wendy Deenik, Walter Pouwels, Jan J. Cornelissen, Karlijn G.M. Smolders, Gert J. Ossenkoppele, Angèle Kelder, B. van Kuijk
Publikováno v:
Janssen, J J W M, Deenik, W, Smolders, K G M, van Kuijk, B J, Pouwels, W, Kelder, A, Cornelissen, J J, Schuurhuis, G J & Ossenkoppele, G J 2012, ' Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib ', Leukemia, vol. 26, no. 5, pp. 977-984 . https://doi.org/10.1038/leu.2011.347
Leukemia, 26(5), 977-984. Nature Publishing Group
Leukemia, 26(5), 977-984. Nature Publishing Group
Insensitivity of chronic myeloid leukemia (CML) hematopoietic stem cells to tyrosine kinase inhibitors (TKIs) prevents eradication of the disease and may be involved in clinical resistance. For improved treatment results more knowledge about CML stem
Autor:
H. Berna Beverloo, Jan J. Cornelissen, Anton Schattenberg, Hanneke C. Kluin-Nelemans, Jeroen Janssen, Pierre W. Wijermans, Gregor Verhoef, Peter J. M. Valk, Augustin Ferrant, Marie José Kersten, Bob Löwenberg, Pieter Sonneveld, Bronno van der Holt, Willem M. Smit, Gert J. Ossenkoppele, S. Wittebol, Marinus van Marwijk Kooy, Petra H. M. Westveer, Roelof Willemze, Wendy Deenik, Leo F. Verdonck
Publikováno v:
Blood, 111(5), 2581-2588. American Society of Hematology
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY
Blood, 111, 5, pp. 2581-2588
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 2581-2588
Contains fulltext : 70504schattenberg.pdf (Publisher’s version ) (Closed access) The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myelo